Agenus Inc. (AGEN) — 2023 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2023; it is not a standalone fourth-quarter report. Agenus is a clinical-stage biotechnology company focused on immuno-oncology, with antibody, cell-therapy and vaccine-adjuvant programs. Its lead program is botensilimab, alone and with balstilimab.
Key financial results
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenue | $156.3 million | $98.0 million |
| Operating loss | $159.5 million | $179.4 million |
| Net loss | $257.4 million | $230.7 million |
| Research and development expense | $234.6 million | $186.7 million |
| General and administrative expense | $78.7 million | $81.0 million |
| Net cash used in operating activities | $224.2 million | $175.4 million |
| Cash, cash equivalents and short-term investments, year-end | $76.1 million | $193.4 million |
- Revenue increased 59% year over year, while net loss widened by $26.8 million. Revenue included $114.6 million of non-cash royalty revenue related to GSK vaccine sales; Agenus previously sold the related royalty stream to HCR. This non-cash revenue is not equivalent to cash receipts.
- R&D expense rose 26%, primarily due to increased third-party services and costs related to antibody programs and the manufacturing facility. G&A expense fell 3%.
- Net interest expense was $97.9 million, up from $61.9 million, largely reflecting non-cash interest associated with the HCR royalty transaction and finance leases. The filing does not provide a meaningful operating margin measure for evaluating the clinical-stage business.
- At year-end, current assets were $112.4 million and current liabilities were $255.9 million. Total stockholders’ deficit was $148.4 million. Principal debt outstanding was $13.1 million, including $13.0 million of subordinated notes due February 2025. The separate liability for sold future royalties and milestones was $257.1 million, of which $132.5 million was classified as current.
Material changes and business developments
- In August 2023, Agenus concentrated resources on botensilimab/balstilimab, temporarily postponing unrelated preclinical and clinical programs and reducing its workforce by approximately 25%.
- Enrollment was completed in October 2023 for the Phase 1 and randomized Phase 2 studies in refractory MSS metastatic colorectal cancer (mCRC) without active liver metastases. In 70 efficacy-evaluable patients, the combination showed a 24% RECIST response rate; 12-month overall survival was 74%, with median overall survival not reached. These reported results are interim and may change.
- Revenue rose from $98.0 million in 2022, which included a $25.3 million HCR sales milestone, to $156.3 million in 2023. The 2023 increase included higher GSK-related non-cash royalty revenue and a $25.0 million BMS milestone. In 2021, revenue was substantially higher at $295.7 million, including $220.0 million of BMS license and milestone revenue.
- Cash and short-term investments declined by $117.2 million from year-end 2022. Agenus sold approximately 84.4 million shares through its at-the-market program during 2023, receiving $133.2 million in net proceeds.
Outlook, risks and unusual items
- Management aims to initiate a U.S. BLA submission for botensilimab/balstilimab in refractory MSS mCRC by the end of 2024, subject to FDA feedback, and plans an EMA submission in the first half of 2025. Phase 2 topline data were expected in the second half of 2024. These are targets, not assurances of filing or approval.
- The FDA had raised questions about whether available data clearly support a particular botensilimab dose; the company planned further discussions with the agency. Fast Track designation does not guarantee accelerated review or approval.
- The auditor’s report includes an explanatory paragraph on substantial doubt about Agenus’s ability to continue as a going concern. Management believes available resources, the BMS milestone received in the first quarter of 2024, and potential financing, partnering, asset-sale and other funding sources may support liquidity through year-end and into 2025. These additional transactions are not assured, and the filing says substantial doubt remains.
- After year-end, Agenus sold approximately 24.0 million shares under its ATM program for about $16.7 million net proceeds through March 8, 2024. Further equity issuance could dilute shareholders. The company also disclosed Nasdaq’s notice regarding its minimum bid-price requirement and a proposed reverse stock split for stockholder consideration.
- Risks include clinical efficacy and safety uncertainty, reliance on external financing and partners, manufacturing scale-up and qualification, competitive and regulatory hurdles, and possible delays or failure to obtain approval. The most common reported botensilimab safety observations included immune-related diarrhea and colitis; Grade 3 treatment-related diarrhea/colitis occurred in approximately 14% of patients.
- The statements received unqualified audit opinions, and the auditor reported effective internal control over financial reporting. The going-concern explanatory paragraph is a significant qualification for investors to consider alongside those opinions.
Important facts for investors to verify
- Whether Phase 2 mCRC results support dose selection and an FDA-acceptable BLA pathway, and whether the expected data and filing milestones were achieved.
- Actual cash burn, unrestricted liquidity, near-term obligations and financing proceeds after the filing date; assess the assumptions underlying management’s runway estimate and the going-concern disclosure.
- How much reported revenue represents cash received versus non-cash GSK royalty accounting, and the continuing accounting and cash-flow effects of the HCR liability.
- Share issuance under the ATM and other financing arrangements, remaining authorization, potential dilution, and Agenus’s Nasdaq listing compliance.
- Progress in qualifying the Emeryville manufacturing facility, partner program changes—including Incyte terminations—and any new material safety, regulatory or clinical findings.